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ABSTRACT
Primary aldosteronism (PA) is characterized by hypertension and sup-
pressed renin activity with or without hypokalemia and comprises the
aldosterone-producing adenoma (APA) and bilateral adrenal hyper-
plasia or idiopatic hyperaldosteronism (IHA). In recent series employing
the aldosterone (aldo, ng/dL):renin (ng/mL·h) ratio (ARR) for screening,
prevalence of PA among hypertensives soars to 8-20%; current predom-
inance of IHA (>80%) over APA suggests the inclusion of former low-renin
essential hypertensives (LREH), in whom plasma aldo can be reduced
by suppressive maneuvers. We evaluated the test characteristics of the
ARR obtained retrospectively from 127 patients with PA (81 APA; 46 IHA)
and 55 with EH (30 LREH; 25 NREH) studied from 1975 to 1990. Using the
combined ROC-defined cutoffs of 27 for the ARR and 12ng/dL for aldo,
we obtained 89.8% sensitivity (Ss) and 98.2% specificity (Sp) in discrimi-
nating PA from EH: all APA and 72% of the IHA patients had values above
these limits, but only one (3%) with LREH. Among the 46 IHA patients, 10
(21.7%) had ARR <27, four of whom with aldo <12ng/dL, virtually indistin-
guishable from LREH. Use of higher cutoff values (ARR≥ 100; aldo ≥20)
may attain 84%Ss and 82.6%Sp in separating APA from IHA. Because IHA
and LREH (“the chaff”) may be spectrum stages from the same disease,
definite discrimination between these entities seems immaterial. Howev-
er, precise identification of the APA (“the wheat”) is critical, since it is the
only surgically curable form of PA. Thus, while patients who may harbor
an APA must be thoroughly investigated and surgically treated, non-
tumoral disease (IHA and LREH) may be best treated with an aldo-recep-
tor antagonist that will also prevent the aldo-mediated inflammatory
effects involved in myocardial fibrosis and abnormal cardiac remodel-
ing. (Arq Bras Endocrinol Metab 2004;48/5:674-681)
Keywords: Low-renin hypertension; Primary aldosteronism; Aldosterone-
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RESUMO
Hiperaldosteronismo primário (HAP) é caracterizado por hipertensão
com renina baixa, com ou sem hipocalemia, compreendendo o ade-
noma produtor de aldosterona (APA) e a hiperplasia adrenal bilateral
ou HA idiopático (HAI). Em séries recentes usando a relação aldos-
terona (aldo, ng/dL):renina (ng/mL·h) (RAR) para rastreamento, a
prevalência de HAP atinge 8-20% dos hipertensos; a predominância
atual do HAI (>80%) sobre APA sugere a inclusão de hipertensos essen-
ciais com renina baixa (HERB), nos quais aldo pode ser suprimida por
expansão de volume. Avaliamos as características do teste RAR, obtido
retrospectivamente de 127 pacientes com HAP (81 APA; 46 HAI) e 55
com hipertensão essencial (30 HERB; 25 com renina normal, HERN) estu-
dados de 1975 a 1990. Usando a combinação de cutoffs de 27 para
RAR e de 12ng/dL para aldo, obtivemos sensibilidade (S) de 89,8% e
especificidade (E) de 98,2% na separação entre HAP e HE: todos os APA
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e 72% dos HAI (mas apenas um [3%] HERB) tinham
valores acima destes limites. Dentre os 46 HAI, 10
(21,7%) tinham RAR <27 e destes, 4 tinham aldo
<12ng/dL, virtualmente indistingüíveis dos HERB. Val-
ores mais elevados de cutoff (RAR≥ 100; aldo ≥ 20)
permitem 84% de S e 82,6% de E na separação entre
APA e HAI. Como HAI e HERB (“o joio”) devem ser
estágios do espectro de uma mesma doença,
parece irrelevante a separação dessas entidades.
Entretanto, identificação precisa do APA (“o trigo”) é
fundamental, por ser a única forma de HAP curável
cirurgicamente. Assim, enquanto a suspeita de um
APA precisa ser criteriosamente investigada e trata-
da cirurgicamente, pacientes com doença não
tumoral (HAI e HERB) podem ser tratados com
antagonistas do receptor de aldo, que também
previnem os efeitos inflamatórios envolvidos no
processo de fibrose e remodelação anormal do
miocárdio. (Arq Bras Endocrinol Metab
2004;48/5:674-681)
Descritores: Hipertensão com renina baixa; Hiperal-
dosteronismo primário; Adenoma produtor de
aldosterona; Hiperaldosteronismo idiopático; Aldos-
terona; Relação aldosterona:renina
THE SYNDROME OF PRIMARY aldosteronism (PA) ischaracterized by “autonomous” or angiotensin-
independent aldosterone excess resulting in sup-
pressed levels of plasma renin activity (PRA). Increased
aldosterone activation of the mineralocorticoid hor-
mone (MCH) receptor in the distal kidney tubule pro-
duces sodium and fluid retention, volume expansion,
renin suppression, and potassium wasting (1). Howev-
er, a distinctive feature of PA, hypokalemia is seldom
observed in current series (2). In contrast with other
florid syndromes of steroid excess (cortisol, andro-
gens), the clinical picture of PA is pale, confined to
hypertension in presence of renal potassium wasting
and, only occasionally, hypokalemia. Thus, except for
some resistance to conventional medical therapy (3-5)
the clinical picture of PA may not be distinct from
essential hypertension.
The archetype of PA is the aldosterone-produc-
ing adrenal adenoma (APA), the first identifiable cause
of the syndrome reported in the mid 50’s by J. Conn.
Bilateral adrenal hyperplasia (also called non-tumorous
and idiopathic hyperaldosteronism [IHA]) was recog-
nized a few years later in several patients submitted to
surgery in the search for an APA. Ever since, APA and
IHA are considered the main subtypes of PA. Because
of their large biochemical, pathologic, therapeutic and
prognostic differences, APA and IHA are not univer-
sally regarded as part of the same syndrome (6-14).
Instead, IHA may well be considered an extreme of
the spectrum of low-renin “essential hypertension”
(LREH) in which plasma or urinary aldosterone levels
are somewhat resistant to suppression.
Until 15 years ago, PA was considered a rare
cause of secondary hypertension (less than 1% of the
hypertensive population) with the APA and IHA sub-
types responding for approximately 80% and 20% of
the cases, respectively (15). Suspicion and identifica-
tion of PA among patients with hypertension was
based mostly on the presence of hypokalemia and fur-
ther demonstration of reduced PRA with elevated and
non-suppressible plasma and urinary aldosterone lev-
els. Lately, with the use of the aldosterone:renin ratio
(ARR) for screening, the prevalence of PA has soared
to a surprising 8 to 20% of the hypertensive population
(16-23), being considered the most frequent cause of
secondary hypertension (24).
Since the unilateral disease (APA) is the sole
form of surgically correctable PA, patients who may
harbor an APA must be carefully scrutinized and later-
alization must be thoroughly pursued with appropriate
adrenal imaging (CT) and adrenal vein sampling for
aldosterone measurements (25,26). On the other
hand, since IHA is not amenable to surgery, it may not
be specifically distinguished from LREH for treatment
purposes.
Because the ARR (in presence of elevated plas-
ma aldosterone concentration [PAC]) seems to be at
present the most convenient test to screen for PA
among hypertensives, we examined in this paper the
best cutoff points for these parameters in a significant
population of previously diagnosed patients with PA
and essential hypertension, in an attempt to separate
PA from EH and, especially, APA (“the wheat”) from
IHA (“the chaff”) in prospective screening.
MATERIAL AND METHODS
We reviewed the hospital charts from 182 patients
admitted for studies in the General Clinical Research
Center at the San Francisco General Hospital Medical
Center (UCSF) or the University Hospital at the
Federal University of São Paulo (UNIFESP) from
1975 to 1990. This 15-year period was chosen
because at that time hypokalemia was virtually manda-
tory for the diagnosis of PA, whereas the aldos-
terone:renin ratio (ARR) was not systematically used
for screening. Computerized tomography (CT) and
adrenal vein sampling (AVS) for aldosterone measure-
ments were already available to confirm the presence
of an APA. From these, 127 patients were found to
have PA, including 81 with an APA (57F/24M, 21 to
57y, median 33] and 46 with IHA due to bilateral
adrenal hyperplasia [23F/23M, 13 to 66y, median
41]. The remaining 55 patients had been labeled as
essential hypertensives, 30 with the low renin variant
(LREH; 20F/10M, 15 to 64y, median 35) and 25
with normal renin levels (NREH; 8F/17M, 19 to 55y,
median 30). All patients were investigated during hos-
pital admission and after equilibration for a period of
3 to 5 days on a metabolic diet containing approxi-
mately 2meq Na and 1meq K per kg of BW per day.
PA was documented by the presence of hyperten-
sion, hypokalemia (in 95% of the cases) or low-normal
plasma potassium levels (3.4-3.7meq/L), suppressed
PRA and normal to elevated PAC and/or urinary aldos-
terone levels, that did not suppress in response to either
a saline infusion test (21 / 2L NaCl 0.9% IV for 4h) (27)
or administration of DOC acetate (10mg IM every 12h
for 3 days) (28). A bonafide APA was excised from every
one of the 81 patients whose previous adrenal CT scans
showed a clear-cut unilateral adrenal lesion and whose
PAC did not increase (in 90% of cases) in response to a
2-4h upright postural stimulation test (29). Diagnosis of
IHA was entertained in 46 patients whose PAC
increased significantly (at least 30% above baseline) after
postural stimulation (in 95% of cases) and in whom a
solitary adrenal mass could not be identified on repeated
adrenal CT scans. Selective AVS for PAC determination
was performed in a few patients whose previous tests
were unrevealing.
After exclusion of other causes of secondary
hypertension by standard evaluation, a diagnosis of
essential hypertension was decided in 55 patients whose
normal to slightly increased PAC and/or urinary aldos-
terone levels were promptly reduced by more than 50%
in response to suppressive maneuvers; 30 of them had
“low” PRA levels (arbitrarily considered as <1 ng/mL·h
on the study conditions) and were considered LREH,
whereas the remaining 25 had normal PRA (≥ 1
ng/mL·h), being classified as NREH.
Individual ARR was calculated from record data
since this ratio was not systematically being used at
that time to screen for PA. In every patient the ARR
was determined by dividing their simultaneously
obtained PAC and PRA values after standing for 2-4hs
while equilibrated on the ward metabolic diet and free
from any possible interfering medication. To avoid
inaccurate interpretation of the ARR, all PRA values
0.2ng/mL·h (detection limit: 0.1ng/mL·h) were
subsequently round up to 0.2 ng/mL·h and a new
“corrected” ARR (cARR) was calculated.
The best diagnostic cutoff points for both the
cARR and PAC that could discriminate PA from
essential hypertension (highest sensitivity and specifici-
ty, or the largest area under the curve) were deter-
mined by analyzing a ROC (receiver operator charac-
teristics) curve where sensitivity was plotted against
specificity (1-specificity) for every value of each para-
meter, from 100% specificity to 100% sensitivity.
Based on the data obtained, a diagram was con-
structed where individual cARR were plotted against
the respective PAC on a semi-logarithmic scale. We
also used distinctive combination of cutoff points for
cARR and PAC to assess sensitivity, specificity and the
positive predictive value in an attempt to discriminate
APA from IHA.
RESULTS
Table 1 presents the mean (±SE) and range for age,
plasma K+, aldosterone (PAC), renin, and the ARR (raw
and corrected) for the 4 groups of hypertensive patients:
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Table 1. Mean±SE [and range] of plasma potassium (K+), aldosterone (PAC), renin activity (PRA), aldosterone:renin ratio
(ARR) and corrected (c)ARR (PRA 0.2ng/mL·h corrected for 0.2) in patients with "primary aldosteronism" (due to an APA -
aldosterone-producing adenoma and IHA - idiopathic hyperaldosteronism) and "essential hypertension" (with low [LREH]
and normal [NREH] renin levels; <1 and  1 ng/mL-h, respectively).
Group n (F/M) Age K+ PAC PRA ARR cARR
(years) (meq/L) (ng/dL) (ng/mL·h) (ng/dL:ng/mL·h)
Primary Aldosteronism
APA 81 (57/24) 37±11 2.9±0.5 53.6±44.7 0.2±0.2 373±459 231±224
[21-57] [2.0-3.8] [12.7-338] [0.1-0.8] [43-3380] [43-1690]
IHA 46 (23/23) 43±12 3.2±0.5 18.9±12.8 0.3±0.2 82.5±81.5 67.8±67.3
[12-66] [1.9-3.8] [7.5-88.9] [0.1-1.0] [14.8-445] [14.8-445]
Essential Hypertension
LREH 30 (20/10) 36±10 4.0±0.2 8.0±3.6 0.5±0.2 18.1±9.5 18.1±9.5
[15-64] [3.4-4.6] [4.3-17.9] [0.2-0.9] [5.1-47] [5.1-47]
NREH 25 (08/17) 32±9 4.1±0.3 8.7±2.0 1.7±0.7 5.5±1.9 5.5±1.9
[19-55] [3.7-4.6] [4.1-13.1] [1.0-3.4] [2.7-9.4] [2.7-9.4]
APA, IHA, LREH and NREH. Mean plasma K+ w a s
significantly reduced in APA and IHA, and PRA also in
LREH (albeit not suppressed), whereas PAC was signi-
ficantly increased in APA and IHA (53.6±44.7 and
18.9±12.8ng/dL, respectively) but not in LR or
NREH (8.0±3.6 and 8.7±2.0ng/dL, respectively).
Mean cARR was significantly increased in APA
(231±224, and above 40 in all patients) and in IHA
(67.8±67.3, but below 20 in 4 [8.7%] patients); among
patients with EH, cARR was below 20 in 19/30
(63.3%) with LREH, and below 10 in all with NREH.
Figure 1 discloses the individual values of PAC in
all 4 groups. Although patients with an APA had the
highest individual values (≥30ng/ dL in 77%, and
≥ 40ng/dL in 50%), some with IHA also had values in
the upper range ( ≥ 30ng/dL in 11%, and ≥40ng/dL in
one [2%] patient). However, a considerable overlap is
observed in the slightly elevated range (from 12 to
20ng/dL) among patients with APA, IHA and LREH.
Figure 2 depicts the two ROC curves built for
the cARR and PAC when subjects were separated
according to the presence of PA (APA and IHA) or
not (LREH and NREH). The best cutoff points
obtained were: 27 (ng/dL:ng/mL·h) for the cARR
(93% sensitivity; 96.5% specificity) and 12 ng/dL for
PAC (94.5% sensitivity; 93.5% specificity).
All individual values of the cARR were plotted
against the respective PAC in figure 3; the dashed cut-
off lines identifies 4 quadrangles: the upper right panel
(cARR≥27 and PAC≥12) defines the typical PA area
(in which all APA and 72% of the IHA were located),
whereas the lower left panel (cARR<27 and PAC<12)
would exclude PA (except for 9% of IHA); the upper
left (cARR ≥ 27 and PAC<12) and the lower right pan-
els (cARR<27 and PAC≥12) encompass patients in
whom the diagnosis of IHA (but not APA) is possible
but less likely. However, 6.5% and 13% of the IHA
patients lie in these areas, respectively.
Figure 4 discloses the percentage of patients
encompassed from each category group (APA, IHA,
LREH and NREH) according to the different com-
bined cutoffs established for cARR and PAC. The com-
bination of a cARR ≥100  and a PAC ≥ 20 has a positive
predictive value of 89.5% in discriminating APA from
IHA (with 84% sensitivity and 82.6% specificity).
DISCUSSION
PA is a common cause of secondary hypertension due
to aldosterone excess in which specific treatment is
available. PA has been diagnosed at increasing rates in
the past 15 years (2,17,21), reaching in some reports
a prevalence as high as 15-30% of the hypertensive
population (2,21,30). Approximately 80% of the cases
are due to non-tumorous disease (bilateral adrenal
hyperplasia or IHA), rather than the prototypic form
of PA, the unilateral APA (17). Thus, identification of
those 20% of patients who may harbor an APA (“the
wheat”) will permit surgical removal of the affected
gland with normalization of blood pressure and elec-
trolyte abnormalities and reduction of mineralocorti-
coid (MCH) receptor-mediated cardiovascular dam-
age (31). The remaining patients with low-renin
hypertension (“the chaff”), regardless of their possible
identification as IHA or LREH, will not benefit from
surgery but instead from specific medical treatment
with aldosterone receptor antagonists as spironolac-
tone and eplerenone that will also reduce potential
cardiovascular complications (32-34).
Until the late 80’s, suspicion of PA was based
solely on the presence of hypertension with
hypokalemia (overt PA), which is only occasionally
observed in present series (17,21). However, during
the past 15 years, screening for PA has been largely
based on the finding of an elevated plasma aldos-
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Figure 1. Individual baseline plasma aldosterone concen-
tration in patients with “primary aldosteronism” (aldos-
terone-producing adenomas [APA, n=81] and idiopathic
hyperaldosteronism [IHA, n=46]) or “essential hypertension”
(low- [LREH, n= 30] and normal-renin [NREH, n=25]).
terone-to-renin ratio (ARR) obtained in unrestricted
or relatively controlled conditions (35-38), regardless
of the presence of hypokalemia. As a consequence,
yearly identification of patients with PA increased
approximately 10 fold in several centers around the
world (2,17) and it is also part of our recent experi-
ence.
When the highly sensitive ARR test replaces the
specificity of hypokalemia in screening for PA, there
may be a potential increase in the rate of false positive
results, making it critical to decide on a test cutoff point
that has high sensitivity without losing specificity. Con-
firmatory procedures are then necessary to establish a
firm diagnosis of PA and to exclude false positives.
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Figure 2. Receiver-operator characteristics (ROC) curves
for plasma aldosterone: plasma renin activity ratios (ARR)
and plasma aldosterone concentration obtained from 127
patients with “primary aldosteronism” (APA and IHA) and 55
with “essential hypertension” (LREH and NREH).
Figure 3. Scattered plot (on a semi-logarithmic scale) correlating plasma aldosterone: plasma renin
activity ratio (ARR) with the corresponding plasma aldosterone concentration in patients with “primary
aldosteronism” (APA and IHA) and with “essential hypertension” (LREH and NREH).
Figure 4. Percentage of patients with “primary aldostero-
nism” (APA and IHA) and “essential hypertension” (LREH
and NREH) that fit the different restriction criteria for ARR and
PAC.
These maneuvers aim to characterize the autonomy of
aldosterone secretion via acute or prolonged expansion
of blood volume with saline infusion (27,39), fludro-
cortisone (2,17) or DOCA administration (2,28),
together with a high sodium chloride intake. However,
the diversity of tests and interpretation criteria (2,40)
associated with different methodology for PRA (or
direct renin) and aldosterone assays may be misleading.
Although interpretation criteria for these tests include a
fall by 50% or more, the level below which plasma or
urinary aldosterone levels should be suppressed to attain
a normal response has been arbitrarily set and varies
widely from 5 to 15 ng/dL or µg/24h, respectively,
producing non-comparable results, which may also be
influenced by pre-test conditions such as patient’s
hydration status, sodium ingestion, posture, time of
sampling, stress, and use of medications. In addition,
reproducibility of these suppression tests has not been
systematically investigated.
Therefore, a segment of the hypertensive popu-
lation defined as non-aldosterone suppressors by one
of these tests (and thus considered PA) may in fact
represent somewhat resistant LREH. Conversely, a
number of IHA patients may suppress aldosterone lev-
els below the arbitrary limit and thus be considered
LREH. This must have been the case in some of our
“IHA” and “LREH” patients (figure 3).
Low renin levels are seen in approximately
20% of the hypertensive population worldwide. In
these LREH patients, aldosterone is usually normal
but inappropriately elevated for the renin level and
this may pose a problem in the differential diagno-
sis with IHA, especially when aldosterone levels are
increased. However, labeling LREH as IHA may
not be important and implies only the addition or
switch to aldosterone receptor antagonists
(spironolactone or eplerenone) as a therapeutic
strategy. This may in fact be appropriate and useful
since the low-renin state may reflect increased
MCH activity (not necessarily aldosterone excess)
(41-45), that has been shown both in experimental
animals and in man (34) to be deleterious to
myocardial plasticity and function. On the other
hand, misdiagnosing IHA as LREH would pre-
clude such patients from specific treatment if an
anti-MCH agent is not considered, leaving them
overexposed to aldosterone excess.
Thus, if one agrees for therapeutic purposes
that IHA and LREH may be stages of a disease con-
tinuum (the non-tumorous low-renin hypertension
syndrome) (12,13,40,46,47) it seems conceivable that
a MCH receptor antagonist should be considered at
least as part of their treatment, regardless of he/she
being diagnosed as IHA or LREH.
The search for an APA among the low-renin
hypertensive patients with an increased ARR is critical
(48). Using the combination of higher cutoff levels for
both the ARR (≥100) and the PAC (≥20) would sig-
nificantly increase the positive prediction for and APA
among patients with the low renin hypertension syn-
drome. At present, missing an APA by current imag-
ing techniques in an otherwise biochemically typical
case would be extremely unusual. If it happens, selec-
tive adrenal vein sampling (AVS) is imperative (26).
When lateralization is documented (with contralateral
suppression of aldosterone production) the presence
of an occult adenoma may be considered and the
gland excised. Based on the present findings it must be
emphasized that marked elevations of the ARR and
PAC is typical of an APA, and an AVS is mandatory if
adrenal imaging is negative. This must have been the
case in 4 of our IHA patients which were clearly out-
liers in the ARR x PAC diagram (figure 3) and in
whom an APA could have been missed by former less-
accurate generation imaging techniques and in whom
AVS was not performed. If there is no clear-cut later-
alization the alternate diagnosis of “primary hyperpla-
sia” must be entertained (49). Because “primary
hyperplasia” (a subset of IHA that responds biochem-
ically as an APA) also responds to surgical reduction of
adrenal mass, subtotal adrenalectomy is indicated (49).
Post-surgical treatment with anti-MCH may neverthe-
less be necessary to control blood pressure.
Easier than missing an adrenal lesion is the
occasional finding of adrenal nodules in an otherwise
biochemically typical IHA. Bilateral adrenal hyperpla-
sia (IHA) may occasionally be associated with the pres-
ence of one or more small or large nodules. Although
a multinodular adrenal hyperplasia will not impose any
special care, the presence of a single or predominant
larger nodule may be tempting for the surgeon. Dif-
ferent from the occasional APA that behaves biochem-
ically as an IHA (angiotensin-responsive APA) and will
certainly benefit from adrenalectomy, an otherwise
typical IHA will not need surgery, even when a large
nodule is present.
In summary, using the combined ROC-defined
cutoff points of 27 for the ARR and 12ng/dL for
PAC, we were able to discriminate patients with pri-
mary aldosteronism (APA and IHA) from those with
essential hypertension (LREH and NREH) with
89.8% sensitivity and 98.2% specificity. Since patients
with an APA (“the wheat”) are the sole ones who will
benefit from surgery, they could be identified (positive
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predictive value of 90%) and separated from other
causes (IHA and LREH, “the chaff”) of the low-renin
hypertension syndrome using a higher combined cut-
off values for the ARR (≥100) and PAC (≥20). How-
ever, imaging procedures and adrenal vein sampling
for aldosterone measurements must be used for con-
firmation. The remaining patients (IHA and LREH)
may not need an accurate discrimination and should
be treated with a MCH-receptor antagonist, either
alone or in combination with additional therapy.
However, one can anticipate that indiscriminate and
widespread use of such agents will hamper the possi-
bility of a definite diagnosis in previously undetected
patients with an APA.
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